DMTTF - Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates | Benzinga
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. (OTCQB: DMTTF) held their respective annual general and special shareholders meeting on October 12. They announced that voting results favored the arrangement plan for the latter’s acquisition by the former.
The TSX Venture Exchange conditionally approved the arrangement. Subject to the approval of BC’s Supreme Court and other customary closing conditions, the arrangement’s effective date would take place on or around October 23, 2023.
Following its completion, Small Pharma will stop trading at both TSXV and the OTCQB venture market, and apply to the Canadian securities authorities to cease being a reporting issuer.
Cybin’s Results
The acquisition of Small Pharma was approved by 43,199,295, 99.41% votes, with 256,200, 0.590% opposing.
In total, there were 66 shareholders represented either in person or by proxy holding 91,903,025 common ...